Discontinuation report IMIPENEM AND CILASTATIN FOR INJECTION USP
Report ID | 144467 |
Drug Identification Number | 02358336 |
Brand name | IMIPENEM AND CILASTATIN FOR INJECTION USP |
Common or Proper name | IMIPENEM AND CILASTATIN FOR INJECTION USP |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | DORMANT |
Active Ingredient(s) | CILASTATIN IMIPENEM |
Strength(s) | 250MG 250MG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 10PSOIJ CA |
ATC code | J01DH |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2021-08-20 |
Remaining supply date | 2021-08-20 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2021-08-23 | French | Compare |
v1 | 2021-08-23 | English | Compare |
Showing 1 to 2 of 2